Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06931405 | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | PHASE2 | RECRUITING | 105 | — | — | May 28, 2025 | Dec 31, 2026 | Feb 17, 2026 | 47 | United States, Denmark +4 |
| Arm | Type | Description |
|---|---|---|
| Arm A1 (Part A): BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Arm A3 (Part A): BLU-808 | EXPERIMENTAL | BLU-808 will be administered orally. |
| Arm B (Part B): BLU-808/Placebo | EXPERIMENTAL | BLU-808 or matching placebo will be administered orally. |
| Name | Type | Description |
|---|---|---|
| BLU-808 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
Key Inclusion Criteria: * Part A: Confirmed diagnosis of CIndU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines. * Part B: Confirmed diagnosis of CSU for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihista...